Nuvo Research and Galderma Laboratories announced that the FDA has approved a supplemental New Drug Application (sNDA) for Pliaglis (lidocaine/tetracaine) 7%/7% Cream for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures (eg, dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal). 

Pliaglis is a topical local anesthetic cream that uses Nuvo’s proprietary phase-changing technology to form a pliable peel on the skin when exposed to air. 

Pliaglis Cream will be available as a 30g tube.

For more information visit or